According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) disclosed its report for the third quarter of 2026. In the first three quarters, the company achieved operating income of 360 million yuan, an increase of 27.79%; net profit attributable to shareholders of listed companies was 31.83 million yuan, turning a year-on-year loss into a profit; deducting non-net profit of 23.61 million yuan, turning a year-on-year loss into a profit; and basic earnings per share of 0.0441 yuan.

According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) disclosed its report for the third quarter of 2026. In the first three quarters, the company achieved operating income of 360 million yuan, an increase of 27.79%; net profit attributable to shareholders of listed companies was 31.83 million yuan, turning a year-on-year loss into a profit; deducting non-net profit of 23.61 million yuan, turning a year-on-year loss into a profit; and basic earnings per share of 0.0441 yuan.